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Abstract 
We report results from a phase 2, randomized, double-blind, 2-period trial (48 weeks each) of domagrozumab and its open-label extension in 
patients with Duchenne muscular dystrophy (DMD). Of 120 ambulatory boys (aged 6 to < 16 years) with DMD, 80 were treated with multiple 
ascending doses (5, 20, and 40 mg/kg) of domagrozumab and 40 treated with placebo. The primary endpoints were safety and mean change in 
4-stair climb (4SC) time at week 49. Secondary endpoints included other functional tests, pharmacokinetics, and pharmacodynamics. Mean (SD) age 
was 8.4 (1.7) and 9.3 (2.3) years in domagrozumab- and placebo-treated patients, respectively. Difference in mean (95% CI) change from baseline 
in 4SC at week 49 for domagrozumab vs placebo was 0.27 (–7.4 to 7.9) seconds ( p = 0.94). There were no significant between-group differences in 
any secondary clinical endpoints. Most patients had ≥1 adverse event in the first 48 weeks; most were mild and not treatment-related. Median serum 
concentrations of domagrozumab increased with administered dose within each dose level. Non-significant increases in muscle volume were observed 
in domagrozumab- vs placebo-treated patients. Domagrozumab was generally safe and well tolerated in patients with DMD. Efficacy measures did 
not support a significant treatment effect. 
Clinicaltrials.gov identifiers: NCT02310763 and NCT02907619 
© 2020 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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1. Introduction 
Duchenne muscular dystrophy (DMD) is an X-linked, 
progressive, neuromuscular disorder caused by mutations in 
https://doi.org/10.1016/j.nmd.2020.05.002 
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the DMD gene that result in a lack of dystrophin protein. 
Dystrophin is critical for membrane integrity in skeletal and 
cardiac muscle cells; its loss leads to skeletal and cardiac 
muscle degeneration [1] . 
Myostatin (growth and differentiation factor 8) is a 
member of the transforming growth factor- β superfamily and 
a negative regulator of skeletal muscle mass [ 2 , 3 ]. Loss or 
inhibition of myostatin in mdx mouse DMD models leads 
to increased muscle mass, increased strength, and decreased 
fat substitution and fibrosis [4-11] . This identifies myostatin 
inhibition as a therapeutic target in multiple neuromuscular 
disorders, including dystrophinopathies. Various strategies to 
inhibit myostatin pharmacologically have been employed, 
including neutralizing antibodies and adnexins, inhibitory 
myostatin propeptides, myostatin receptor-Fc fusion protein, 
follistatin the endogenous inhibitor of myostatin and 
myostatin receptor blocking antibodies [12] . 
Domagrozumab, a humanized recombinant 
immunoglobulin (Ig)G1 antibody that binds to myostatin, 
and inhibits its activity, was evaluated for treatment of DMD. 
Wild-type and mdx mice treated with the murine equivalent 
of domagrozumab RK35 had significant increases in body 
weight, lean body mass, and grip strength. Cynomolgus 
monkeys treated with domagrozumab showed significant 
dose-dependent increases in lean muscle mass and muscle 
volume, but no functional test was conducted [9] . 
A randomized phase 2 trial of domagrozumab 
evaluated safety, efficacy, pharmacokinetics (PK), and 
pharmacodynamics (PD) of multiple ascending doses of 
domagrozumab in ambulatory boys with DMD. Patients who 
completed the phase 2 trial were invited to participate in an 
open-label extension (OLE) trial to evaluate the long-term 
safety, efficacy, PK, and PD of domagrozumab. We report 
results from both trials. 
2. Materials and methods 
2.1. Patients 
Ambulatory boys aged 6 to < 16 years with genetically 
confirmed DMD were enrolled if they were able to perform 
the 4-stair climb (4SC) in ≥2.5 but ≤12 seconds at screening, 
and were receiving glucocorticosteroids for ≥6 months, with 
a stable regimen for ≥3 months prior to guardians signing the 
informed consent. Other inclusion criteria included adequate 
hepatic and renal function. 
Exclusion criteria included: underlying disposition for 
iron accumulation or bleeding disorder; cognitive impairment 
or behavioral issues that would have affected the conduct 
of the study; history of surgery within 6 weeks, or 
planned surgery during the study; any injury that may 
impact function testing; compromised cardiac function (left- 
ventricular ejection fraction [LVEF] < 55% as determined 
on cardiac MRI or echocardiogram [ECHO] screening); 
current or prior treatment with anti-myostatin; exon skipping; 
nonsense mutation–targeted therapies; or treatment with 
utrophin modifiers within the preceding 30 days or for > 30 
days in total. 
Patients were included in the OLE if they completed the 
phase 2 trial through week 97, had adequate hepatic function, 
glutamate dehydrogenase (GLDH) ≤20 units/L, iron content 
estimate within the normal range on a liver MRI, and provided 
consent. 
2.2. Standard protocol approvals, registrations, and 
participant consent 
A phase 2 trial (B5161002; ClinicalTrials.gov: 
NCT02310763) and an OLE trial (Study B5161004; 
ClinicalTrials.gov: NCT02907619) were investigated. Both 
studies were conducted in accordance with legal and 
regulatory requirements, as well as the general principles set 
forth in the International Ethical Guidelines for Biomedical 
Research Involving Human Subjects, guidelines for Good 
Clinical Practices, and Declaration of Helsinki. The protocols, 
any amendments, and informed consent/assent documents 
were approved by the institutional review board or ethics 
committee at each study center. Parent or legal guardians 
provided written, informed consent prior to any study-specific 
activity being performed. 
2.3. Study design and treatment 
The phase 2 trial was a randomized, 2-period, double- 
blind, placebo-controlled, multiple ascending dose (5, 20, and 
40 mg/kg) study of domagrozumab vs placebo in ambulatory 
boys with DMD. The trial was conducted between November 
24, 2014 and November 23, 2018, in patients from 31 sites 
in 8 countries. 
Patients were stratified by 4SC time ( ≤ or > 8 seconds) at 
baseline and randomly assigned to 1 of 3 sequence groups. 
Randomization into sequence groups (treatment assignment) 
was generated using an Interactive Response Technology 
System by unblinded, dispensing personnel. The first exposure 
to domagrozumab was a within-patient dose escalation (5, 20, 
and 40 mg/kg) for 48 weeks; subsequent exposure continued 
at 40 mg/kg, determined to be the maximum tolerated dose in 
the dose escalation period, in both the phase 2 and OLE trials. 
In Sequence 1, domagrozumab within-patient dose escalation 
(period 1) was followed by domagrozumab in weeks 49–96 
(period 2). In Sequence 2, domagrozumab within-patient dose 
escalation in the first 48 weeks was followed by placebo 
in weeks 49–96. In Sequence 3, placebo in the first 48 
weeks was followed by domagrozumab within-patient dose 
escalation in weeks 49–96 ( Fig. 1 ). Patients received treatment 
for 96 weeks, i.e., two treatment periods of 48 weeks each, 
without pause between periods. 
At each dose level, the study drug was administered over 2 
hours by IV infusion every 4 weeks for a total of 16 weeks (4 
doses; Fig. 1 ). At the initiation of the phase 2 trial, individual 
dose escalation for each patient occurred after review of all 
available safety data through the planned fourth dose within 
each dose level until the External-Data Monitoring Committee 
agreed, after a number of patients had completed the first 
48 weeks of the phase 2 trial, that dose escalation could 
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Figure 1. Phase 2 trial (Study B5161002) design. OLE, open-label extension (B5161004). 
proceed without individual safety review for the remainder 
of the study. Patients in the OLE trial were to be treated with 
domagrozumab every 4 weeks for up to 4 years. 
The phase 2 trial and the OLE trial were terminated in 
August 2018 after the analysis of phase 2 trial data (described 
below) showed there was no significant treatment effect vs 
placebo in the primary efficacy endpoint (4SC) and other 
functional endpoints. 
2.4. Procedures and outcomes 
The primary objectives of the phase 2 trial were safety 
and tolerability of multiple ascending, repeat IV doses of 
domagrozumab and efficacy at 49 weeks based on an 
observed mean change from baseline in 4SC time (assessed 
every 8 weeks) in patients treated with domagrozumab vs 
placebo. The primary objective of the OLE trial was long- 
term safety of domagrozumab in boys with DMD. 
Safety assessments in the two trials included: frequency 
and severity of incidence of abnormal and clinically relevant 
laboratory findings; physical examinations; vital signs; EKG, 
LVEF by cardiac MRI or ECHO (determined by site 
preference); liver MRI R2 ∗ monitoring iron accumulation 
[13] ; and the Columbia Suicide Severity Rating Scale. 
AEs of special interest included, liver iron accumulation, 
precocious puberty and epistaxis (seen with ACE-031, a less 
selective myostatin inhibitor) [14] . GLDH, a liver-specific 
injury biomarker was added to monitor for drug-induced liver 
injury in addition to transaminases, which are elevated from 
dystrophic muscle in DMD. 
The North Star Ambulatory Assessment (NSAA) [15-17] , 
range of motion using goniometry [18] , Performance of Upper 
Limb (PUL) [ 19 , 20 ], 6-minute-walk distance (6MWD) [21] , 
pulmonary function based on forced vital capacity (FVC) 
using spirometry [ 17 , 22 ], and strength assessed by hand-held 
myometry were conducted every 8 weeks in the phase 2 
trial and every 24 weeks in the OLE. Secondary functional 
endpoints were assessed as mean change from baseline vs 
placebo during the first 49 weeks in the phase 2 trial. In the 
OLE trial, all functional assessments, including 4SC time, 
were assessed as change from overall baseline (beginning of 
phase 2) and change from OLE baseline. In both studies, 
change from baseline for all functional assessments was also 
analyzed by sequence group. 
To characterize long-term effect following 96 weeks 
treatment with domagrozumab, data were compared with 
a historical control group derived from the Cooperative 
International Neuromuscular Research Group (CINRG) DMD 
natural history database [ 23 , 24 ]. The control cohort from 
CINRG was selected to closely match the population for 
age, glucocorticosteroid usage, baseline 4SC time, ambulatory 
status, and baseline LVEF ≥55%. The historical control 
group was first compared with Sequence 3 (placebo group 
in the phase 2 trial) by evaluating the mean change from 
baseline at week 49 to assess similarities between the two 
untreated populations. The historical control group was then 
compared to Sequence 1 to evaluate the mean change from 
baseline at week 97. Matched control data were selected 
by comparing the baseline criteria to all available visits 
in the CINRG database. Some patients in the historical 
control group had multiple eligible baseline visits eligible 
for comparison matching enrollment criteria (with a follow- 
up visit 96 ± 9 weeks later), and in these cases their 
baseline visit was chosen at random for the week 97 analysis. 
The same approach was used for the week 49 analysis for 
historical control patients with eligible baseline visits and 
follow-up visits 48 ± 4 weeks later. 
Secondary PD endpoints specific to the phase 2 trial 
included changes in thigh muscle volume on MRI (every 12 
weeks) [ 25 , 26 ] and modulation of myostatin in serum (every 
4 weeks). A prespecified subgroup analysis was performed to 
assess treatment effects in a subgroup of patients with baseline 
4SC ≥3.5 to ≤8 seconds who may be more rapidly declining 
with lower variability over a 1-year period [27] . 
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In the OLE trial, pulmonary function tests also included 
forced expiratory volume in 1 second and peak expiratory 
flow rate. Ambulatory status was reviewed at each visit in 
the OLE trial. Loss of ambulation in OLE was defined as the 
inability to walk ≥10 meters unassisted and without braces, 
and in the historical control group as daily wheelchair use. 
The functional health status as assessed by the Pediatric 
Outcomes Data Collection Instrument (PODCI) was an 
exploratory endpoint, which was completed by parents or 
caregivers of children aged ≤10 years; the adolescent self- 
report version was completed by patients ≥11 years old [28] . 
Other clinical outcomes assessments in the OLE assessed 
the long-term effects of domagrozumab on: (i) health-related 
quality of life using the EuroQoL–5 Dimensions 3 Levels 
(EQ-5D-3L) and healthcare resource utilization in boys with 
DMD; and (ii) caregiver burden due to child’s DMD, using 
the Zarit Burden Interview (ZBI) and work productivity 
and activity impairment using the Work Productivity and 
Activity Impairment questionnaire adapted for the caregiver 
(WPAI:CG) [29] . 
Blood samples for PK, anti-drug antibody (ADA), and 
neutralizing antibody analyses were collected during the 
96 weeks of the study and were analyzed using validated 
analytical methods. PK parameters included maximum serum 
concentration (C max ); time to C max (T max ); trough (predose) 
serum concentration (C trough ); serum concentration at the 
end of planned 2-hour infusion (C 2 ); area under the serum 
concentration–time curve over the dosing interval τ (AUC τ ), 
where τ = 4 weeks (672 hours); and the average serum 
concentration over the dosing interval (C av ). C max , T max , and 
C trough were derived from serum of all patients treated with 
domagrozumab. AUC τ , C av , and drug clearance were derived 
from patients with additional PK sampling who received 
domagrozumab in the first 48 weeks. 
2.5. Statistical analysis 
The planned sample size of 105 patients for the phase 
2 trial was designed to detect a 2.5-second difference in 
change from baseline to week 49, in 4SC time, between 
domagrozumab and placebo treatment, assuming a common 
SD of 4.0 seconds with 80% power at α = 0.05 (2-sided), 
a 2:1 treatment allocation, 1 interim analysis for futility 
prior to the primary analysis, and 10% attrition rate. All 
analyses were based on the full analysis set, which included 
all randomized patients who received ≥1 dose of study drug. 
Patients assigned to Sequence 1 and Sequence 2 (i.e., treated 
with domagrozumab through week 48) were analyzed together 
and compared with patients in Sequence 3 (i.e., treated with 
placebo through week 48). 
In the phase 2 trial, the primary efficacy endpoint, 
change from baseline in 4SC time, was analyzed using 
a longitudinal mixed-effects model for repeated measures 
(MMRM). The baseline result, treatment, time, and treatment 
by time interaction, were included as fixed effects in the 
model. Patients were included as a random effect and the 
model was fit with an unstructured covariance for the repeated 
measures. The distribution of the 4SC time was assumed to 
be right-skewed. Negative values in 4SC mean improvement. 
Transformations (including log transformation) of the 4SC 
time were evaluated to ensure the normality assumption was 
met. Contrasts were created to estimate the differences in 
change from baseline, in 4SC time, at the end of each dose- 
treatment level for the first 48 weeks (weeks 17, 33, and 49). 
The final analysis of the primary endpoint was performed at 
week 49, though data continued to be collected through week 
97. 
Missing data were handled using maximum likelihood 
techniques for MMRM. This analysis is unbiased under 
the assumption of missing at random when the model 
assumptions hold (i.e., missingness is unrelated to the missing 
values, had they been observed). Patients who lost the 
ability to complete a functional assessment and/or ambulate 
were assumed to be missing not at random. Additional 
imputation methods to assess the sensitivity of the analysis to 
missing not at random data were also performed and included 
completer analyses (i.e., patients who reached week 49), and 
transforming time to complete a functional assessment to 
velocity, so that patients with a missing time were assumed 
to have a velocity of zero. 
Secondary endpoints were analyzed using the same 
longitudinal mixed model as described for the primary 
endpoint. In the prespecified subset of patients with an 
anticipated rapid disease decline ( > 1 year), the mean change 
on functional tests from baseline vs placebo was evaluated. 
MRI of the right thigh was acquired without the use of 
contrast, using a proton density weighted spin-echo sequence 
with 5 mm slices and 0 mm gap to cover the entire 
thigh (knee-to-hip). Imaging data were sent to BioTelemetry 
Research (Cardiocore & VirtualScopics, Rochester, NY) for 
quality evaluation and analysis. In addition to thigh muscle 
volume measurements, muscle volume index measurements 
were calculated based on whole thigh MRI images. Muscle 
volume index is a measure of the fraction of the total thigh 
tissue that is lean muscle[30] and was calculated as follows: 
(muscle volume / [muscle volume + inter/intra-muscular fat 
volume]) ×100 
PK population for serum concentration included all 
patients who received ≥1 dose of domagrozumab and had 
≥1 concentration value reported. The population for PK 
parameters included all patients who received ≥1 dose of 
domagrozumab and had ≥1 PK parameter calculated. The 
population for myostatin serum concentration included all 
patients who had ≥1 concentration value reported. 
3. Results 
3.1. Patients 
Of 162 patients with DMD who were screened for study 
entry, 121 enrolled and 120 were treated (Supplementary 
material – Fig. S1). Key reasons for screening failure were 
4SC < 2.5 seconds and LVEF < 55%. Mean age at baseline 
was 8.7 (range, 6–15) years. The mean (SD) weight in 
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Table 1 
Patient demographics and baseline characteristics by sequence group. 
Sequence 1 Sequence 2 Sequence 3 
n = 41 n = 39 n = 40 
Age, mean (SD), year 8.3 (1.9) 8.5 (1.5) 9.3 (2.3) 
Race, n (%) 
White 33 (80.5) 33 (84.6) 35 (87.5) 
Black 1 (2.4) 0 1 (2.5) 
Asian 6 (14.6) 5 (12.8) 4 (10.0) 
Other 1 (2.4) 1 (2.6) 0 
Weight, mean (SD), kg 29.9 (8.5) 30.3 (8.8) 35.3 (14.4) 
Range 14.8–48.8 16.4–50.1 19.0–86.4 
BMI, mean (SD), kg/m 2 19.4 (3.9) 19.5 (3.8) 20.7 (5.8) 
Height, mean (SD), cm 123.2 (8.0) 123.6 (8.9) 128.9 (9.3) 
Glucocorticosteroids usage, n (%) 
Deflazacort 25 (61.0) 20 (51.3) 25 (62.5) 
Prednisone or prednisolone 16 (39.0) 19 (48.7) 15 (37.5) 
4SC time, s 
Mean (SD) 5.2 (2.5) 5.0 (3.3) 5.3 (2.8) 
6MWD, meters 
Mean (SD) 357.9 (99.0) 374.0 (99.2) 350.8 (84.9) 
NSAA: Time to complete 10-m run/walk, s 
Mean (SD) 6.5 (1.9) 5.7 (1.3) 6.4 (1.8) 
NSAA: Time to stand from supine, s 
Mean (SD) 7.1 (5.1) 7.7 (5.9) 7.7 (3.8) 
NSAA score, s 
Mean (SD) 19.5 (6.7) 21.5 (7.1) 20.2 (7.2) 
PUL: overall score 
Mean (SD) 66.8 (4.0) 67.0 (5.2) 67.1 (3.2) 
4SC = 4-stair climb; BMI = body mass index, NSAA = North Star 
Ambulatory Assessment; PUL = performance of upper limb. 
Sequence 3 (35.3 [14.4] kg) was higher than that in Sequence 
1 (29.9 [8.5] kg) and Sequence 2 (30.3 [8.8] kg), which 
was driven by two patients with weights of 86.4 kg and 
81.8 kg each. Most patients were on a high daily dose 
of glucocorticosteroids. Other demographics and baseline 
characteristics were comparable across all sequence groups 
( Table 1 ). 
By week 49, seven patients discontinued from the phase 2 
trial because of: unwillingness to participate in study (n = 3), 
lost to follow-up (n = 1), AE (n = 1), and other reason (n = 2). 
By week 97, 48 patients discontinued due to early termination 
of the trial, 65 patients completed 96 weeks of the phase 
2 trial, and 59 were treated in the OLE. All 59 patients 
discontinued the OLE: 55 because of early termination of 
the trial, 1 death (unrelated to study drug), 1 moved away 
from the site, and 2 no longer willing to participate. 
3.2. Safety 
In the first 48 weeks of the phase 2 trial, 115 patients 
experienced all-causality, treatment-emergent AEs (TEAEs; 
Table 2 ). Five patients had 6 serious AEs (appendicitis and 
anxiety, superior sagittal sinus thrombosis, femur fracture, 
troponin increased, and femoral neck fracture); none were 
considered drug-related. TEAEs by sequence in the phase 2 
weeks 49–96 and OLE were similar to those in the first 48 
weeks. 
Table 2 
Treatment-emergent, all-causality AEs, by Sequence and total in the first 48 
weeks of the Phase 2. 
No. of Patients, Phase 2 a , b Sequence 1 Sequence 2 Sequence 3 Total 
Evaluable for AEs 41 39 40 120 
Number of AEs b 263 222 286 771 
AEs 39 38 38 115 
Serious AEs 1 1 0 2 
Severe AEs 2 3 2 7 
Discontinued due to AEs 1 c 0 0 1 c 
Dosing temporarily 
discontinued due to AEs 
3 5 8 16 
Includes all data collected since the first dose of study drug in the first 48 
weeks. AE baseline was defined as the last predose assessment prior to each 
individual dose level. If the same patient in a given sequence had more than 
one occurrence in the same preferred-term event category, only the most 
severe occurrence was taken. 
AE = adverse event. 
a Medical Dictionary for Regulatory Activities (v21.0) coding applied. 
b Except for the Number of AEs, patients are counted only once per 
sequence in each row. 
c Discontinuation due to serious AE (exacerbation of pre-existing anxiety). 
In the OLE trial, all 59 patients had all-causality TEAEs, 
4 had severe AEs, and 1 discontinued due to AE of lethal 
fat embolism syndrome from tibial fracture. Five patients had 
8 serious AEs (ileus paralytic and volvulus, fat embolism, 
appendicitis, seizure, angina pectoris, and troponin increase); 
none were considered drug-related. 
There were no safety concerns identified for all AEs 
of special interest, including epistaxis, precocious puberty, 
or hepatic iron accumulation. GLDH > 3 ×upper limit of 
normal (ULN) was observed in one patient each in the 
domagrozumab and placebo groups. Elevation of GLDH 
< 3 ×ULN was comparable between the two treatment 
groups. 
There was no difference between domagrozumab- and 
placebo-treated patients in cardiac TEAEs, and no consistent 
pattern of change in LVEF related to cardiac TEAEs between 
treatment groups. At week 97, mean changes (SD) from 
baseline in LVEF by both cardiac MRI and ECHO were –
3.9 (5.6), –1.6 (5.4), and –0.9 (6.2) for Sequences 1, 2, and 
3, respectively. Patients in Sequence 1 who had exposure to 
domagrozumab for 96 weeks had a nominally greater but 
non-statistically significant decrease in LVEF compared with 
Sequences 2 and 3, where exposure to domagrozumab was 
limited to 48 weeks. Elevations in cardiac troponin I were 
not sustained or associated with clinical symptoms. The AE 
of troponin increased was reported as related to treatment 
in 3 patients (2 treated with placebo and 1 treated with 
domagrozumab) in the first 48 weeks. 
3.3. Efficacy 
The primary endpoint of mean change in 4SC time at 
week 49 was not met in the phase 2 trial ( Fig. 2 ). Based 
on the MMRM analysis, the difference in mean change in 
4SC time from baseline to week 49 for domagrozumab vs 
placebo was 0.27 seconds (95% CI: –7.4, 7.9; p = 0.94). All 





























Week 9 Week 17 Week 25 Week 33 Week 41 Week 49
Visit
Domagrozumab vs Placebo
Figure 2. Mean (95% CI) change from baseline on 4SC for domagrozumab vs placebo at week 49. 4SC, 4-stair climb. 
Table 3 
Primary and sensitivity analyses for 4SC in phase 2 trial at week 49. 
Mean Change From 
Baseline to Week 49 
Domagrozumab, Sequence 
1&2 Combined, Mean (SE) 
Placebo, Mean (SE) Difference, Domagrozumab 
vs Placebo, Mean (95% CI) 
p Value 
4SC, MMRM, s 8.28 (2.15) 8.01 (3.03) 0.27 (–7.40, 7.90) 0.94 
Log-transformed 4SC, 
MMRM, log s 
0.30 (0.05) 0.40 (0.08) –0.10 (–0.28, 0.09) 0.29 
Log-transformed 4SC 
changes, MMRM, % 
– – –9.4 (–24.7, 8.9) 0.29 
Completer a analysis 4SC, 
MMRM, s 
1.88 (0.74) 2.75 (1.04) –0.87 (–3.42, 1.67) 0.50 
4SC velocity, MMRM, 4 
stairs/s 
–0.05 (0.01) –0.06 (0.01) 0.02 (–0.01, 0.05) 0.30 
4SC subgroup: baseline 4SC 
≥3.5 & ≤8 s 
Full analysis set 3.62 (0.94) 3.53 (1.16) 0.094 (–3.08, –3.27) 0.95 
Completer a analysis 1.53 (0.62) 2.49 (0.76) –0.97 (–2.9, 1.0) 0.33 
PPAS of 4SC, s 7.03 (2.02) 7.77 (2.79) –0.75 (–7.98, 6.49) 0.83 
Wilcoxon test of 4SC, rank 
score 
45.53 52.86 –7.33 0.22 
Wilcoxon test of velocity 
4SC, rank score 
59.23 52.59 6.64 0.31 
4SC = 4-stair climb; MMRM = mixed model for repeated measures; PPAS = per protocol analysis set. 
a Completer is defined as patient with 4SC data at week 49. Patients with missing 4SC values at week 49 have been excluded. 
sensitivity analyses showed directionally favorable but non- 
statistically significant results with domagrozumab ( Table 3 ). 
There were no significant differences in the mean change from 
baseline on the 4SC between the domagrozumab and placebo 
in the prespecified subgroup, based on baseline 4SC time at 
all measurements ( Table 3 ). 
The mean change in 4SC at week 49 in the placebo 
group was similar to the historical control group (difference, 
0.211; 95% CI: –2.835, 3.257; p = 0.8908). These findings 
suggest the historical control dataset can serve as an adequate 
control group for the analysis of 4SC at week 97. There was 
no significant difference in mean change in 4SC time from 
baseline to week 97 between Sequence 1 and the historical 
control group; the difference using MMRM was 0.819 
seconds (95% CI: –1.451, 3.090; p = 0.4748). Also, there was 
no significant change in 4SC time between Sequence 1 and 
the historical control group from overall baseline to week 
170 in the OLE trial (difference, 10.57; 95% CI: –1.313, 
22.463; p = 0.0811). In the OLE, there was a mean increase 
from overall baseline to week 146 of 6.784 seconds (95% 
CI: 0.749, 12.819) observed in the 4SC time among 15/59 
evaluable patients across the 3 treatment sequences. 
No significant treatment differences were found for the 
analysis of FVC, percent predicted FVC, NSAA, 6MWD, 
myometry-based muscle strength, or PUL ( Table 4 ). There 
was no significant difference in time to loss of ambulation 
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Table 4 
Key secondary and exploratory endpoints in Phase 2 trial at Week 49. 
Mean Change From 
Baseline to Week 49 
Domagrozumab, Sequence 
1&2 Combined, Mean (SE), n 
Placebo, Mean (SE), n Difference, Domagrozumab 
vs Placebo, Mean (95% CI) 
P Value 
FVC, MMRM, L 0.11 (0.03), 74 0.15 (0.04), 38 –0.042 (–0.12, 0.04) 0.30 
Predicted FVC, MMRM, % –0.24 (2.02), 74 0.07 (2.65), 38 –0.31 (–6.08, 5.46) 0.92 
NSAA 
Total score –3.6 (0.7), 73 –5.2 (0.9), 37 1.6 (–0.5, 3.8) 0.13 
Time to complete 10 m 
run/walk, MMRM, s 
1.23 (0.23), 58 1.20 (0.33), 26 0.034 (–0.67, 0.73) 0.92 
Time to stand from supine, 
MMRM, s 
3.08 (1.08), 51 2.42 (1.43), 25 0.667 (–6.06, 7.40) 0.71 
6MWD, MMRM, m –58.0 (9.3), 61 –56.5 (12.7), 30 –1.5 (–30.0, 27.0) 0.92 
Myometry-based muscle strength 
Right knee extension -1.13 (0.29), 75 -0.98 (0.39), 37 –0.15 (–1.01, 0.71) 0.73 
Left shoulder abduction –0.32 (0.18), 74 –0.30 (0.24), 37 –0.02 (–0.57, 0.52) 0.93 
Right shoulder abduction –0.30 (0.23), 74 0.14 (0.31), 37 –0.44 (–1.17, 0.29) 0.23 
PUL, overall score –1.4 (0.4), 74 –1.3 (0.5), 38 0 (–1.3, 1.2) 0.94 
PUL, shoulder level score –1.0 (0.3), 75 –1.1 (0.4), 38 0.1 (–0.9, 1.1) 0.83 
PUL, middle level score –0.4 (0.2), 74 –0.2 (0.3), 38 –0.2 (–0.8, 0.4) 0.51 
PUL, distal level score –0.1 (0.1), 74 –0.2 (0.1), 38 0.2 (–0.1, 0.5) 0.27 
PODCI 
Transfer and basic 
mobility core scale 
–11.1 (2.00), 73 –15.1 (2.75), 35 4.1 (–2.02, 10.13) > 0.05 
Sports and physical 
functioning 
–11.1 (2.03), 73 –13.9 (2.79), 35 2.8 (–3.17, 8.86) > 0.05 
Pain/comfort –4.1 (2.47), 73 –8.1 (3.38), 35 4.0 (–3.69, 11.63) > 0.05 
Happiness –9.5 (2.36), 73 –10.8 (3.24), 35 1.4 (–5.87, 8.60) > 0.05 
Global functioning –7.7 (1.60), 73 –11.5 (2.20), 35 3.8 (–1.15, 8.71) > 0.05 
6MWD = 6-minute-walk distance; FVC = forced vital capacity; MMRM = mixed model for repeated measures; NSAA = North Star Ambulatory Assessment; 
PODCI = Pediatric Data Collection Instrument; PUL = performance of upper limb. 
from the OLE baseline throughout the OLE trial between 
Sequence 1 and the historical control group ( p = 0.3011). In 
the OLE, 17 (of 59) patients experienced loss of ambulation 
(Sequence 1: n = 3, Sequence 2: n = 7, Sequence 3: 
n = 7). 
3.4. Clinical outcomes assessments 
Decreases from overall baseline for the PODCI parent- 
reported scores were observed in all 5 items and the Global 
Functioning Scale over the course of both trials ( Table 4 ). 
The least decrease from overall baseline was seen for the 
pain/comfort core scale (mean change at week 146, –6.3; 
95% CI: –13.6, 1.1). The greatest decrease from overall 
baseline was for transfer and basic mobility core scale (mean 
change at week 146, –21.1; 95% CI: –32.6, –9.7). A change 
from baseline in the adolescent self-report measure was 
not performed due to the limited number of baseline visit 
assessments. 
There was no change in general health status (EQ-5D-3L, 
EQ-5D-Youth) and health resource utilization from baseline 
of the OLE trial throughout its course. There was no change 
in caregiver burden from OLE baseline through the end of 
the OLE (mean change in ZBI total score, –0.6; 95% CI: –
3.4, 2.3, among 18/59 evaluable patients at week 49). Impact 
on work productivity and activity impairment was observed 
from OLE trial baseline throughout the course of the OLE 
trial in all 4 items of the WPAI:CG: mean change at week 
49 was 2.3 (95% CI: –2.632, 7.224) for percent worktime 
missed, 7.1 (95% CI: 0.2, 14.1) for percent impairment while 
working, 9.2 (95% CI: 2.496, 15.871) for percent overall work 
impairment, and 8.9 (95% CI: 1.1, 16.7) for percent activity 
impairment. 
3.5. Pharmacokinetics 
Median serum concentrations of domagrozumab increased 
with increasing dose level for patients within each dose level 
(first 48 weeks and weeks 49–96) following domagrozumab 
IV administration at 5, 20, and 40 mg/kg. Following repeated 
administration at 40 mg/kg, median serum concentrations 
remained generally constant for patients during weeks 49–
96 in Sequence 1. C trough values generally increased from 
the first dose of domagrozumab through the last dose, 
within each dose level during escalation. The C trough values 
appeared in steady-state by the last dose of within-patient 
dose escalation in all sequences and remained at steady-state 
with domagrozumab 40 mg/kg in Sequence 1, weeks 49–
96. PK parameters for domagrozumab following the first and 
last dose administration at each dose level for patients, with 
additional PK sampling in the first 48 weeks, (Sequences 1 
and 2) are described in Table 5 . 
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Table 5 
PK parameters of domagrozumab for patients with additional PK sampling in the first 48 weeks (Sequences 1 and 2). 
Parameter, units Domagrozumab Parameter Summary Statistics a by Week 
5 mg/kg IV 20 mg/kg IV 40 mg/kg IV 
Week 1 Week 13 Week 17 Week 29 Week 33 Week 45 
First 48 weeks, n b , c 
N b 2 2 2 2 2 2 






C 2 , μg/mL 119, 147 113, 181 410, 574 522, 680 870, 1160 1140, 1160 
C av , μg/mL 32.3, 46.6 43.9, 59.2 151, 207 192, 261 322, 406 424, 568 
C max , μg/mL 119, 147 115, 181 410, 574 522, 680 870, 1160 1160, 1220 
C trough , μg/mL NR 20.6, 22.6 20, 29.6 100, 127 107, 116 193, 257 
T max , hr 2.08, 2.25 2.13, 4.42 2.15, 2.17 2.05, 2.08 2.13, 2.17 2.17, 5.67 
CL, mL/hr/kg NC 0.126, 0.17 NC 0.114, 0.155 NC 0.105, 0.14 
Weeks 49 –96 d 
N, n, n1, n2 b 5, 5, 5, 5 5, 5, 5, 5 4, 4, 3, 4 5, 5, 4, 4 4, 4, 4, 4 –
AUC τ , μg •hr/mL 24670 (31) 40070 (21) 117700 (8) 183000 (14) 293200 (21) –
C 2 , μg/mL 126.2 (12) 158.2 (18) 499.5 (7) 683 (12) 1221 (15) –
C av , μg/mL 36.72 (31) 59.63 (21) 175.3 (8) 272.1 (14) 436.3 (21) –
C max , μg/mL 126.2 (12) 158.2 (18) 501.6 (7) 687.5 (14) 1227 (16) –
C trough , μg/mL NR 28.71 (23) 28.09 (14) 135.2 (20) 147.9 (20) –





CL, mL/hr/kg NC 0.1247 (21) NC 0.1092 (14) NC –
AUC τ = area under the serum concentration–time curve during a dosing interval; C 2 = serum concentration at the end of planned 2 hr infusion; C av = average 
drug concentration; CL = drug clearance; C max = maximum serum concentration; C trough = trough serum concentration; CV = coefficient of variation; NC = not 
calculated; NR = not reported; T max = time to reach maximum serum concentration. 
a Summary statistics were not presented if fewer than 3 patients have reportable parameter values. The minimum and maximum were reported. 
b N = number of patients in the treatment group in the indicated population; n = number of patients contributing to the summary statistics; n1 = number of 
patients contributing to the summary statistics for AUC τ , CL, and C av ; n2 = number of patients contributing to the summary statistics for C max and T max . 
c Individual patient values were presented for n < 3. 
d Geometric mean (geometric %CV) for all except: median (range) for T max . Geometric means not presented for C trough when individual values include 0. 
3.6. Serum myostatin pharmacodynamics and imaging 
biomarkers 
An increase in baseline total serum myostatin 
(domagrozumab-bound and free myostatin) post 
domagrozumab treatment was observed for all the treatment 
sequences. Total serum myostatin C trough levels were slightly 
higher for all dose levels compared with placebo. There were 
no apparent dose-specific trends observed for total myostatin 
C trough levels. 
The MMRM analysis showed no significant differences 
between domagrozumab and placebo in mean percent change 
from baseline on thigh muscle volume measures on MRI at 
weeks 17, 33, and 49. This analysis includes measurement 
of whole thigh muscle volume and whole thigh inter/intra- 
muscular fat volume. Although there were no significant 
differences in mean percent change from baseline, for 
both muscle volume and muscle volume index, there were 
directionally favorable differences between domagrozumab 
and placebo; the differences (domagrozumab to placebo) at 
weeks 17, 33, and 49, respectively, were 2.19%, 2.11%, and 
2.86% for whole thigh muscle volume and 0.76%, 1.76%, and 
1.98% for thigh whole muscle volume index. 
3.7. Immunogenicity 
Based on all immunogenicity samples tested in the phase 
2 trial, only 1 sample in one patient in Sequence 3 had 
a positive ADA titer ( ≥1.88), which was at week 65; the 
patient’s subsequent samples were negative for ADA. No 
participants in the OLE trial tested positive for ADA. 
4. Discussion 
Multiple ascending, monthly doses of domagrozumab at 
5, 20, and 40 mg/kg were generally safe and well tolerated. 
The phase 2 trial did not meet its primary efficacy endpoint 
of mean change from baseline in 4SC time at week 49. 
Sensitivity analyses all showed directionally favorable, but 
non-statistically significant and not clinically meaningful 
treatment effects with domagrozumab vs placebo. 
Potential etiologies for the disappointing outcome in this 
trial include different PD of domagrozumab in humans versus 
mice, recent finding of marked reduced baseline myostatin 
levels in patients with DMD suggesting a more severe 
downregulation of the myostatin pathway in patients with 
DMD compared with mdx mice, and/or other ligands not 
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impacted by domagrozumab playing an important role in 
primate muscle mass regulation [31] . Another potential reason 
for lack of efficacy relates to the recent finding, identified 
after the protocol initiation, that in the mdx mice, daily 
glucocorticosteroids administration were shown to interfere 
with potential benefits associated with myostatin inhibition 
[32] ; however, the murine homolog of domagrozumab 
mRK35, produced similar increases in body weight and 
lean muscle mass in control and mdx mice with and 
without prednisolone treatment [33] . With the more recent 
negative clinical results from other myostatin inhibitors (e.g., 
bimagrumab, ACE-083, RG6206) in multiple muscle wasting 
diseases, a comprehensive review of myostatin inhibition as 
a target for human muscle wasting diseases is warranted. 
The majority of patients experienced ≥1 TEAE. The 
incidence of AEs was comparable between domagrozumab 
and placebo, and among the 3 dose levels of domagrozumab. 
AEs were mostly mild and moderate and consistent with those 
reported previously in patients with DMD [ 14 , 34-36 ]. None 
of the reported serious AEs were considered drug-related. 
Preliminary data showed numerically greater LVEF decline 
with domagrozumab exposure at weeks 97 vs 49. The final 
data showed decrease in risk, but although the quantitative 
difference in LVEF was neither statistically different nor 
considered clinically meaningful, the event was classified 
as a potential risk, with the implication for additional 
monitoring. 
The 4SC functional test was selected as the primary 
efficacy endpoint for this trial based on results of prior 
glucocorticosteroid trials [37-39] , and because it is considered 
a reliable measure of motor function [ 27 , 40 ]. A mean 
change of 4.7 ± 7.5 seconds in 4SC time at week 48 
was demonstrated in patients aged ≥7 years treated with 
glucocorticosteroids (placebo arm) [27] . This difference is 
greater than the minimal clinically important difference, i.e., 
clinically meaningful value of 2.1–2.2 seconds for 4SC 
calculated by McDonald et al. [41] . An assumed change of 
2.5 seconds (as determined a priori) from baseline in the 
4SC time in patients treated with domagrozumab vs placebo 
may suggest both a statistically significant and clinically 
meaningful change. 
Although neither muscle volume nor muscle volume index 
measures were statistically significant in this study, they are 
both consistent with a potential anabolic effect. The measure 
of muscle volume index is of particular interest in patients 
with DMD, because as the disease progresses, the percent 
of total muscle volume decreases, whereas fatty replacement 
of the muscle increases [30] . This study confirms the ability 
to obtain reproducible and valid thigh muscle volume and 
muscle volume index measures in an international multicenter 
trial in a DMD population. 
Among PODCI subscales, mobility and function scores 
can distinguish between functional milestones in patients with 
DMD [ 23 , 42 , 43 ]. A difference was seen in the domains of 
upper extremity and physical function core scale, transfer 
and basic mobility core scale, pain/comfort core scale, 
and global functioning scale. Although natural history data 
suggest PODCI subscales scores, especially mobility-related, 
can distinguish between functional milestones representative 
of disease progression in patients with DMD [ 23 , 42 ], little 
data exist with respect to responsiveness of PODCI scores to 
treatment. 
Total serum myostatin levels were increased with 
domagrozumab treatment as the binding of myostatin to 
domagrozumab serves to sequester myostatin. The binding 
of an antibody to its ligand increases the total plasma 
levels of the ligand; because the ligand takes on the 
properties (distribution and clearance) of the free antibody 
[44] . Total myostatin in the serum accounts for myostatin 
bound to domagrozumab and free myostatin. Based on the 
concentrations of domagrozumab in the serum, > 95% of 
serum myostatin was bound (derived from a PK/PD analysis 
to be published elsewhere) and unable to interact with its 
target receptor. The systemic exposures increased with each 
domagrozumab dose escalation and systemic exposures were 
consistent with the predictions in healthy volunteers [ 45 , 46 ]. 
Several points may be useful for interpretation of our 
findings and for design of future studies. This was the first 
trial of domagrozumab in patients, and the lack of data in 
patients led to a complicated study design, which was difficult 
to execute. The 4SC measure may not be an optimal primary 
efficacy endpoint to assess treatment effect of myostatin 
inhibition; as true for other functional measures in DMD, 
4SC is affected clinically by other confounders (e.g., ankle 
contractures and weight gain) and not solely related to muscle 
strength. It does, however, reflect an activity important for 
daily living. There is an emerging consensus that NSAA 
may be the best outcome measure for ambulatory patients 
with DMD [47-50] . However, the lack of efficacy in several 
secondary function and biomarker endpoints is consistent with 
the lack of efficacy in the 4SC measurement and suggests 
that the selection of 4SC as the primary endpoint was not 
the sole cause for the negative outcome in this trial. The 2- 
year outcomes were compared with historical control group 
as there was no true 2-year placebo group in this study, but 
this allowed all patients with rare disease the opportunity to 
receive an active drug. Also, despite using some functional 
criteria to exclude outliers, a number of outliers were still 
present. This, together with the non-random distribution of 
missing the primary endpoint data, posed challenges for the 
MMRM analysis. 
In conclusion, domagrozumab was generally safe and well 
tolerated in this population of patients with DMD. The phase 
2 trial did not meet its primary efficacy endpoint. In addition, 
the totality of evidence, including secondary endpoints, did 
not support a significant treatment effect with domagrozumab, 
which led to termination of both trials. The studies were not 
terminated due to safety reasons. 
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